ImageneBio (NASDAQ:IMA) Issues Earnings Results

ImageneBio (NASDAQ:IMA) issued its quarterly earnings data on Thursday. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.25), FiscalAI reports.

ImageneBio Stock Performance

IMA traded down $0.62 during midday trading on Friday, reaching $5.29. 75,284 shares of the company were exchanged, compared to its average volume of 1,023,482. The stock has a market capitalization of $56.34 million, a P/E ratio of -0.66 and a beta of 0.73. ImageneBio has a one year low of $3.94 and a one year high of $18.00. The stock’s 50-day simple moving average is $5.71 and its 200 day simple moving average is $6.60.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of ImageneBio from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, ImageneBio currently has an average rating of “Hold” and an average target price of $26.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock worth $74,000 after acquiring an additional 6,810 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in ImageneBio during the 4th quarter worth approximately $76,000. Millennium Management LLC bought a new position in ImageneBio during the 4th quarter worth approximately $79,000. T3 Companies LLC bought a new position in ImageneBio during the 4th quarter worth approximately $91,000. Finally, Jane Street Group LLC bought a new position in ImageneBio during the 4th quarter worth approximately $103,000. Institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.